A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus
Status and phase
Completed
Phase 1
Conditions
Type 1 Diabetes Mellitus
Treatments
Drug: Magnesium Chloride
Drug: Humalog diluent
Drug: Treprostinil
Drug: Sodium Citrate
Study type
Interventional
Funder types
Industry
Identifiers
Details and patient eligibility
About
The main purpose of this study is to evaluate the effect of excipients sodium citrate and treprostinil without insulin on local infusion site pain in participants with type 1 diabetes mellitus (T1DM) on continuous subcutaneous insulin infusion (CSII). The study may last up to 36 days including a screening period and 3 visits.
Enrollment
40 patients
Sex
All
Ages
18 to 69 years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- T1D for at least 1 year and continuously using insulin for at least 1 year
- Using an insulin pump for at least the last 6 months
- Have hemoglobin A1c (HbA1c) value of ≤ 9.0%
- Have a body mass index (BMI) within the range of 18.5 to 35.0 kilograms per square meter (kg/m²)
- Have medical and laboratory test results that are acceptable for the study
- Have venous access sufficient to allow for blood sampling
Exclusion criteria
- Hemophilia or any other bleeding disorder
- Have a pathologic tuning fork test as assessed with a Rydel-Seiffer tuning fork
- Are taking anesthetics or pain medication regularly or intermittently which could interfere with interpretation of pain scale
- Have had more than 1 episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia) within the last 90 days prior to screening
- Have had more than 1 emergency room visit or hospitalization due to poor glucose control (hyperglycemia or diabetic ketoacidosis) within the last 6 months prior to screening
- Have any hypersensitivity or allergy to any of the diluents or excipients used in this trial
- Have or used to have health problems or medical test results that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
- Have participated, within the last 30 days, in a clinical trial involving an investigational product
- Have used or are currently using Lyumjev® as part of their standard insulin therapy
Trial design
Primary purpose
Basic Science
Allocation
Randomized
Interventional model
Crossover Assignment
Masking
Double Blind
40 participants in 5 patient groups
Sequence 1:Arm Region,Abdomen 6mm,Buttock,Abdomen 9mm,Thigh
Experimental group
Description:
Participants had cannulas inserted into each of the designated infusion sites (6 millimeter (mm) for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated subcutaneously (SC) with 15 millimolar (mM) sodium citrate and 1 microgram per milliliter (μg/mL) treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 unit per hour (U/h). The same procedure occurred at subsequent infusion sites with an approximately 30-minute (min) interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
Treatment:
Drug: Sodium Citrate
Drug: Treprostinil
Drug: Humalog diluent
Drug: Magnesium Chloride
Sequence 2:Abdomen 6mm,Abdomen 9mm,Arm Region,Thigh,Buttock
Experimental group
Description:
Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
Treatment:
Drug: Sodium Citrate
Drug: Treprostinil
Drug: Humalog diluent
Drug: Magnesium Chloride
Sequence 3:Abdomen 9mm,Thigh,Abdomen 6mm,Buttock,Arm Region
Experimental group
Description:
Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
Treatment:
Drug: Sodium Citrate
Drug: Treprostinil
Drug: Humalog diluent
Drug: Magnesium Chloride
Sequence 4:Thigh,Buttock,Abdomen 9mm,Arm Region,Abdomen 6mm
Experimental group
Description:
Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 units per U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
Treatment:
Drug: Sodium Citrate
Drug: Treprostinil
Drug: Humalog diluent
Drug: Magnesium Chloride
Sequence 5:Buttock,Arm Region,Thigh,Abdomen 6mm,Abdomen 9mm
Experimental group
Description:
Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
Treatment:
Drug: Sodium Citrate
Drug: Treprostinil
Drug: Humalog diluent
Drug: Magnesium Chloride
Trial contacts and locations
2
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems